Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089193 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
A Phase 2 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089193: Completed Phase 2 study, sponsored by Craig L Slingluff, Jr.
NCT00089193 is a Phase 2 study that has completed, run by Craig L Slingluff, Jr. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089193, a Phase 2 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients with stage II B, stage IIC, stage III, or stage IV melanoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL multi-epitope melanoma peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Phase | Phase 2 |
What the finished NCT00089193 record still lists
NCT00089193 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00089193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089193 about?
NCT00089193 is a clinical study titled "Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and k...
What is the current status of trial NCT00089193?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-09.
What interventions are being tested in trial NCT00089193?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089193?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia